Abstract:OBJECTIVE:This study aimed to identify predictors of intracranial in-stent restenosis (ISR) after stent placement in symptomatic intracranial atherosclerotic stenosis (ICAS). METHODS:The authors retrospectively collected data from consecutive patients who suffered from symptomatic ICAS and underwent successful stent placement in Beijing Tiantan hospital. Eligible patients were classified into "ISR," "indeterminate ISR," or "no-ISR" groups by follow-up digital subtraction angiography or CT angiography. A multivariate logistic regression model was used to explore the predictors of intracranial ISR after adjustments for age and sex. In addition, ISR and no-ISR patients were divided into two groups based on the strongest predictor, and the incidence of ISR, recurrent stroke, and symptomatic ISR was compared between the two groups. RESULTS:A total of 511 eligible patients were included in the study: 80 ISR, 232 indeterminate ISR, and 199 no-ISR patients. Elevated high-sensitivity C-reactive protein (hs-CRP; odds ratio [OR] 4.747, 95% confidence interval [CI] 2.253-10.01, p < 0.001), Mori type B and C (Mori type B vs Mori type A, OR 3.119, 95% CI 1.093-8.896, p = 0.033; Mori type C vs Mori type A, OR 4.780, 95% CI 1.244-18.37, p = 0.023), coronary artery disease (CAD; OR 2.721, 95% CI 1.192-6.212, p = 0.017), neutrophil/lymphocyte ratio (NLR; OR 1.474 95% CI 1.064-2.042, p = 0.020), residual stenosis (OR 1.050, 95% CI 1.022-1.080, p = 0.001) and concurrent intracranial tandem stenosis (OR 2.276, 95% CI 1.039-4.986, p = 0.040) synergistically contributed to the occurrence of intracranial ISR. Elevated hs-CRP (hs-CRP ≥ 3 mg/L) was the strongest predictor for ISR, and the incidence of ISR in the elevated hs-CRP group and normal hs-CRP group (hs-CRP < 3 mg/L) was 57.14% versus 21.52%, respectively, with recurrent stroke 44.64% versus 16.59%, and symptomatic ISR 41.07% versus 8.52%. CONCLUSIONS:Elevated hs-CRP level, NLR, residual stenosis, Mori type B and C, CAD, and concurrent intracranial tandem stenosis are the main predictors of intracranial ISR, and elevated hs-CRP is crucially associated with recurrent stroke in patients with symptomatic ICAS after intracranial stent implantation.

The Association Between Cyp2c19 Genotype and of In-Stent Restenosis among Patients with Vertebral Artery Stent Treatment

Multiple predictors of in-stent restenosis after stent implantation in symptomatic intracranial atherosclerotic stenosis.

Predictors of in-stent stenosis and occlusion after endovascular treatment of intracranial vascular disease with the Willis covered stent.

The Long Term Results Of Vertebral Artery Ostium Stenting In A Single Center

Cause Analysis and Treatment of Vertebral Artery Stenosis Angioplasty Restenosis

Risk Factors Associated With Outcomes of Non-cardioembolic Ischemic Stroke In Patients Stratified By Essen Stroke Risk Score

The Association between CYP2C19 Genetic Polymorphism and Prognosis in Patients Receiving Endovascular Therapy

Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis

Arterial occlusions increase the risk of in-stent restenosis after vertebral artery ostium stenting

Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.

Long-Term Risk Factors for Intracranial In-Stent Restenosis from a Multicenter Trial of Stenting for Symptomatic Intracranial Artery Stenosis Registry in China

Risk factors ofrestenosis in postoperative patients with vertebral artery stenosis treated by endovascular stent implantation

Gene polymorphism of rennin-angiotensin system and in-stent restenosis after percutaneous transluminal coronary angioplasty plus stenting

Risk factors associated with recurrence of ischemic stroke after intracranial stenting in china: a case-control study

Relationship between cytochrome P450 2C19 polymorphisms and clinical outcomes in clopidogreltreated patients who underwent cerebrovascular stenting placement

Incidence and Predictors of the In-stent Restenosis after Vertebral Artery Ostium Stenting.

Influence of Vessel Size and Tortuosity on In-Stent Restenosis after Stent Implantation in the Vertebral Artery Ostium.

Effect of CYP2C192 and 3 on clinical outcome in ischemic stroke patients treated with clopidogrel.

The Incidence and Risk Factors of In-Stent Restenosis for Vertebrobasilar Artery Stenting

Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.

Variant Recurrent Risk among Stroke Patients with Different CYP2C19 Phenotypes and Treated with Clopidogrel